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Abstract 
The aim of this research was study of the effects of steroids on cardiovascular risk factors in the male bodybuilders.Ten athlete 
bodybiulders served as the experimental group, those who were taking Oxymetholone drug during a period of 6 weeks exercise 
training, and 10 athletes (only exercise training)  served as the control group. Blood samples were taken before and after the 
athletes took the drugs and training. Considering the pre-test and post-test, the data were studied by using t-teas. The results 
showed that at the level of  Į = 0.05 , there was significant difference in concentration of HDL-c in experimental group.Also 
there was no significant difference in LDL-c,Colestrol total and Triglyceride in both experimental and control groups.In the other 
hand, steroids abusing decrease HDL-c which it can increase cardiovascular risk factors in the athletes that use this drugs.  
© 2009 Elsevier Ltd. 
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1.Introduction 
The misuse of androgenic-anabolic steroids (AAS) in young, healthy strength athletes has been associated with the 
occurrence of premature cardiovascular events¹. These events may in part be mediated by the adverse effectson 
serum lipid variables that have been linked to AAS administration. Previous studies have indicated that the useof 
AAS results in decreases in high density lipoprotein cholesterol (HDL-C) and apolipoprotein A1 (Apo-A1; themajor 
component of the HDL particle), and increases in low density lipoprotein cholesterol (LDL-C)³. A growing number 
of strength athletes misuse AASs to obtain a well shaped body or increase muscular strength. Most athletes take 
AASs. for periods of 6–12 weeks several times a year . Self administration of AASs may result in much higher 
doses than recommended, with possibly more severe side effects and more profound effects on serum lipids and 
lipoproteins. In particular, the orally active 17-a-alkyl steroids have been shown to have severe effects on LDL-C 
and HDL-C 4. Various studies have suggested that the concentration of lipoprotein (a) (Lp(a)) is an independent risk 
indicator for the development of vascular disease 7. The fat composition of Lp(a) is comparable to that of LDL-C, 
but the most important difference is the presence of a specific apoprotein(a) 8. This protein is attached to 
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apolipoprotein B (Apo-B)by a disulphide bridge. A close correlation has been reportedbetween the serum  
concentration of Lp(a) and the accumulation of this particle in the vascular wall 9. The serum concentration of Lp(a) 
seems to be genetically determinedand, when raised, cannot be lowered by alterations in food intake or taking 
cholesterol lowering drugs ¹¹. Previous reports have suggested that, in contrast with their detrimentale ffects on 
lipids, AASs may favourably lower Lp(a)concentrations¹². 
2. Method 
This study was part of a larger one exploring the effects ofAASs on body composition, exercise performance, and 
health status in male strength athletes.20 Subjects were recruited  in regional gym clubs. All volunteers completed 
an extensive questionnaire with questions on health status, history, training habits, and the use of AAS ,and had a 
full physical examination to exclude any relevant diseases.Inclusion criteria were: male; bodybuilding training 
experience of at least three years; at least four strength training workouts a week or eight hours of strength training a 
week; aged 20–25 years. The following exclusion criteria were set: hypertension, diabetes mellitus, liverdisease or 
abnormal liver enzyme serum concentrations,hereditary hypercholesterolaemia, raised serum cholesterol, infertility, 
and smoking.Ten self administered AAS for six weeks in addition to their usual strength training(AAS group) and 
ten controls performed strength training without using AAS(CO group).The subjects in the CO group had never 
used AASs. All subject in the AAS group had previous experience of AAS self administration. On average, they had 
started AASuse 3.5 years previously .The participants were expected to have been drug free for at least three months 
before the start of the study. The subjects in the AAS group purchased the AAS on the black market. They 
administered 
Oxymetholone (the strongest oral steroid).At baseline, and after 6 weeks of AAS use, blood was drawn from the 
antecubital vein after a10 hour fast, for the measurement of serum lipids and lipoproteins. 
3.Statistical Analysis 
Serum total cholesterol and triglycerides were determined by enzymatic methods on a Cobas Bio analyser. HDL-C 
and LDL-c  was measured enzymatically with poly(ethylene glycol) 6000. The data were studied by using t-
test.(SPSS 12). 
4. Result 
AAS use led to no significant changes in serum Triglycerides, total cholesterol and  but a considerable increase (6%) 
in LDL-C was found, and a significant fall in HDL-c (35%). 
There were no considerable changes in control group in all factors. figures below show these results: 
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Figur 1. Comparison between means of pre and post tests in control group.No significant difference in all factors in    
control group
Imanipour.Vahid et al. / Procedia Social and Behavioral Sciences 1 (2009) 2843–2846 2845
142.75142.87
85.87
94.37
48.8
35.6
70.2
76
0
20
40
60
80
100
120
140
160
Cho TG HDL LDL
pre- test
post- test
Figure2. Comparison between means of pre and post tests in experimental group. Significant difference in HDL factor in experimental group
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Figure 3. Comparison means of post tests between control and experimental groups. significant difference in HDL factor in experimental group 
after 6 weeks drug using and exercise training 
Discussion 
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This study demonstrated an increase in LDL and a significant decrease in HDL. Most studies in this field found so 
changes. HDL decrease in this study, consistent with the data from¹º. In his study, he found significant decrease in 
HDL. Also Applebam (1987). Showed such changes in his researches.Decrease in HDL and increase in LDL are 
results of increase in hepatic lipase activity 6. The results indicate that the misuse of androgenic-anabolic steroids 
(AAS) decrease HDL and increase LDL. These changes may be associated with the occurrence of premature 
cardiovascular events
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